[Review of a new immunosuppressive drug: enteric-coated mycophenolate sodium (Myfortic)].
Sánchez-Fructuoso
A I
AI
Servicio de Nefrología, Hospital Clínico San Carlos, Madrid. sanchezfruct@telefonica.net
D002455:Cell Division / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000517:prevention & control; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D015994:Incidence; D016030:Kidney Transplantation; D008214:Lymphocytes / Q000187:drug effects / Q000378:metabolism; D015337:Multicenter Studies as Topic; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D009711:Nucleotides / Q000378:metabolism; D016032:Randomized Controlled Trials as Topic; D013608:Tablets, Enteric-Coated
D007166:Immunosuppressive Agents; D009711:Nucleotides; D013608:Tablets, Enteric-Coated; D007168:IMP Dehydrogenase; C488211:IMPDH1 protein, human; C501687:IMPDH2 protein, human; D009173:Mycophenolic Acid